What the FDA labels say about taking them together
Denosumab and romosozumab
Romosozumab's FDA label of July 16, 2026 names denosumab in its warnings and precautions section; the denosumab labels PlainMeds reads (4) do not name romosozumab. The romosozumab label: “Concomitant administration of drugs associated with ONJ may increase the risk of developing ONJ.”
Check it at the source: the denosumab FDA label on DailyMed (effective June 23, 2026, Amgen, Inc); the romosozumab FDA label on DailyMed (effective July 16, 2026).
What does the denosumab label say about romosozumab?
Denosumab's label (effective June 23, 2026) and its 3 other brand-application labels do not name romosozumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (XGEVA), Amgen, Inc, effective June 23, 2026 (SPL set 628f0998-1206-4001-aeee-18133aa9f3bf), via openFDA; the full label on DailyMed
What does the romosozumab label say about denosumab?
Romosozumab label, warnings and precautionsConcomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase the risk of developing ONJ.
Source: FDA drug label (Evenity), Amgen, Inc, effective July 16, 2026 (SPL set 471baba2-7154-4488-9891-0db2f46791e7), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Denosumab | Romosozumab | |
|---|---|---|
| Labeled for | Osteoporosis | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1,862.74 per mL 60 mg/mL syringe | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once